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ABSTRACT
Protein ligation is a process integral to many biomedical applications, however the current
industry standard, expressed protein ligation (EPL), is highly error prone and time-and-cost
inefficient. Our team sought to improve this integral process by proving the efficacy of a new
method of protein ligation using the transpeptidase Sortase A. Sortase A is known to efficiently
bind two peptide fragments so long as they are attached to LPXTG motifs, which signal and
activate the enzyme’s ligation abilities. Previous studies affirm Sortase A’s binding ability and
efficacy in in vitro situations, however none have yet confirmed its abilities in vivo. Operating in
vivo would not only allow us to take advantage of Sortase A’s binding abilities, but also the
mammalian expression system’s own protein editing mechanisms, namely its high fidelity
protein synthesis and post translational modification capabilities. This proof-of-concept project
used Green Fluorescent Protein (GFP) fragments as a simple but qualitative method of
measuring Sortase A’s in vivo binding abilities, causing the cells to fluoresce if the introduced
GFP fragments were successfully bound together. Our team found that Sortase A does in fact
have the capacity to operate in vivo, signified by fluorescence in our test subject and further
confirmed by our positive and negative controls. These findings indicate a bright future for
Sortase A’s role as a protein ligate, and a basis for future studies on how to further optimize and
regulate its abilities to further improve protein ligation and its many applications.
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Chapter 1: Introduction
1.1 Background and Motivation
Protein ligation is a pivotal process within a variety of biomedical applications, providing
researchers a path through which they can produce or link synthetic proteins for therapeutic and
research purposes. The ability to create proteins with specific functionalities is key to producing
more advanced therapeutics to treat the complex diseases plaguing our society today.
Additionally, the ability to link protein tags allows researchers to better track and understand the
functional processes that take place within the human body, giving scientists a means through
which they can explore and learn about human biology in previously impossible ways. As such
an integral process to the development of medicines and understanding of the body, protein
ligation methods must be as robust as possible, both to ensure a product’s quality and to allow for
more complex innovation. Our team identified current methods as functional, but nowhere near
the level of efficiency or specificity necessary to drive forward scientific innovation, motivating
us to look for improvements and alternatives to the current industry standards.
1.2 Industry Standard
The current industry standard to ligate proteins is Expressed Protein Ligation (EPL). EPL relies
on inteins, which are proteins known for removing themselves from larger protein sequences and
binding the adjacent protein segments together. In this way, inteins can also ligate two proteins
together in vitro [1]. Though EPL is commonly used, it is flawed for several reasons. For one,
there is a low final product yield after purification. This is because the intein binds proteins
together but fails to fold the protein correctly, rendering it useless. The chemical mechanism of
EPL also creates extra cysteine residues on the final protein, which increases the likelihood of
side reactions and further decreases purity. In addition, EPL requires large amounts of reagents to
complete the reaction; since inteins are not enzymes, the reaction requires a 1:1 ratio of protein
to intein to occur. Lastly, EPL is only able to semi-synthesize proteins, rather than create novel
proteins. This means that it is able to bind two pre-existing proteins together but cannot link
smaller peptide fragments to create a new protein. Overall, EPL has much room for improvement
in the areas of product yield, product purity, user ease, and sustainability [2].
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1.3 Chemical Mechanism
Sortase A is a transpeptidase enzyme naturally found in gram-positive bacteria cells, originally
found in S. aureus [3]. This enzyme has two functions: attach proteins to the peptidoglycan cell
wall and create pili that project from the bacterial surface. These two reactions follow a similar
process and require an LPXTG motif, part of the cell wall sorting signal (CWSS) [4]. The
LPXTG motif is found in many surface proteins in these bacterial cells, making it an ideal signal
for sortase A. The full CWSS contains the LPXTG motif on the N terminus, a hydrophobic
domain, and a positively charged tail located inside the cell. This tail is critical for keeping the
protein anchored in the cell wall [5]. The Sortase A prefers the leucine, proline, threonine and
glycine in the first, second, fourth, and fifth positions respectively to optimize kinetics. Sortase A
has no preference for the amino acid in the fourth position [6]. Variants of the LPXTG motif
have only been recorded at the X and T positions; T has been replaced by A and X by D, E, A,
N, Q, or K [7].
The Sortase A mechanism forms as a result of linking a bacterial membrane peptide to a lipid, as
seen in Figure 1. Sortase A first recognizes the LPXTG motif on the CWSS of the surface
protein by performing a nucleophilic attack to the carbonyl carbon between the threonine and
glycine residues [6]. This results in the formation of a tetrahedral intermediate that quickly
reduces to a thioacyl intermediate [4]. The second peptide, lipid II, is then recognized by sortase
A. This substrate performs the second nucleophilic attack to the same carbonyl carbon, resulting
in an unstable tetrahedral formation via the formation of an amide bond. Sortase A is then kicked
out, resulting in the formation of the final product: protein - lipid II [8]. This is then incorporated
into the peptidoglycan cell wall through other cell wall reactions [4].
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Figure 1. Sortase A mechanism in gram-positive bacteria cells (Picture obtained from Choppa 2020). The surface
protein precursor of sortase A is created, and is guided to the secretory pathway using the sorting signal. The protein
precursor is then embedded into the cell wall, where the LPXTG motif is recognized by Sortase A. The first
nucleophilic attack results in the formation of a Sortase A - peptide intermediate, leaving the result of the peptide in
the cell wall. Lipid II then performs a nucleophilic attack on the intermediate, resulting in the cross-link of a
peptide-lipid that is incorporated into the bacterial cell wall [8]

1.4 Current Applications
Bioconjugation has been explored as another function of Sortase A to replace current industry
standards. Sortase A has been able to conjugate two peptides, a peptide and a protein, and two
proteins together in vitro [10]. The enzyme has been used as a cross linker in fields like tissue
engineering, which require high specificity and efficiency [11]. Other non-protein molecules
have been able to be conjugated as well, including vitamins such as folate through the addition of
a triglycine group [10]. This functionality lends itself to applications such as molecular sensing,
surface modification, and biomaterials [12]. While many studies have focused on in vitro
applications of Sortase A, very few have achieved success with in vivo applications.
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Sortase A has been found to tag certain proteins and substrates together in vivo, using a method
called sortagging [13]. Sortagging is a method of labeling specific proteins using small probes of
less than 2 kDa [14]. Although this use of Sortase A shows promise in understanding protein
function, the applications of Sortase A can be expanded further.
1.5 Click Chemistry
Click chemistry is also known as a group of fast reactions that are easy to perform, high yielding,
easily purifiable, and versatile [15, 16]. Click chemistry has many applications ranging from
materials to pharmaceutical science, and also has applications in proteomics and nucleic
research. One of the biggest downsides of click chemistry is most mechanisms require copper as
a catalyst [17, 18]. The use of copper in click chemistry is trivial for practical applications in
vivo, as copper can be cytotoxic and cause cell death [19]. However in applications where copper
is not needed as a catalyst, click chemistry is able to offer powerful tools for labeling in vivo
[20]. Still there is a need to overcome these limitations of click chemistry and offer an alternative
method of bioconjugation in vivo.
1.6 Bioconjugation of Sortase A
In order for Sortase A to properly function in vivo, the sortase A enzyme, the LPXTG motif, and
the signal probe, usually a pentaglycine, need to be expressed inside mammalian cells [9]. This
mechanism will be similar to its mechanism inside bacterial cells; the reaction will need to be
mediated by two nucleophilic attacks to produce a fully functional protein as seen in Figure 2.
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Figure 2. Sortase A mechanism in vivo (Picture obtained from Choppa 2020). This proposed mechanism will
require two plasmids, one coding for the Sortase A enzyme, and another for the two peptide halves. Sortase A will
attack the LPXTG motif of the first peptide, resulting in a peptide-sortase A intermediate. The pentaglycine on the
second polypeptide will then nucleophilically attack the intermediate, resulting in the formation of a fully functional
protein [8].

1.7 Project Goal
The goal of our project is to create a new method of in vivo protein ligation using the
transpeptidase enzyme, Sortase A, to bind peptide fragments together to create a fully functional
protein. This method should improve upon the current industry standards for protein ligation to
create a method that is faster, less complex, and produces higher yields of product. To prove the
success of this new method, a plasmid containing two nonfunctional fragments of green
fluorescent protein (GFP) and a plasmid encoding for Sortase A will be introduced into the cell.
Sortase A will respond to a particular motif within the GFP peptide fragments and ligate the two
sequences together to create a fully functional GFP molecule. Success of the experiment will be
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monitored qualitatively using a fluorescent microscope and quantitatively using a Fluorescent
Activated Cell Sorter (FACS).
1.8 Objectives and Expected Results
Several experiments and cell types are needed to confirm Sortase A’s ability as a protein ligase.
First, the plasmids containing Sortase A, enhanced GFP (eGFP), and the GFP peptide fragments
are transformed into e.coli cells. After transformation, the bacterial cells are scaled up to a larger
volume. These experiments are to amplify the plasmids before mammalian cell work. Next, the
plasmids are extracted from the bacterial cells and purified using a procedure called miniprep.
The purity of our miniprep results is confirmed using gel electrophoresis. In this experiment, the
expected results are two bands around the designed plasmid length, indicating pure plasmid
DNA. If additional bands appear, this indicates the presence of contamination, such as genomic
DNA or cellular debris. The next half of the experiments are performed using mammalian cells.
HeLa cells are thawed and cultured to create a healthy stock of cells for the experiment. Once
cells recover from thawing, they are transfected with the purified plasmid DNA. Transfected
cells are monitored every 24 hours for three days using the fluorescent microscope. The well
containing eGFP is expected to fluoresce, as well as the test wells containing normal to high
affinity fragments of GFP and Sortase A. The wells containing isolated GFP fragments or
isolated Sortase A are not expected to fluoresce, since the experiment requires the combination
of peptides and Sortase. Lastly, a well containing a mix of Sortase A and low affinity GFP
peptides is used as another negative control and is not expected to fluoresce.
1.9 Back-Up Plan
The original plan for the project consisted of two main parts: proving a new method of in vivo
protein ligation and proving that Sortase A can be controlled for selective and time-dependent
use. The first half of the project was expected to take the first four months to complete. First, the
plasmids would be transformed into bacterial cells and amplified. Then, the plasmids would be
extracted using Miniprep and confirmed pure using gel electrophoresis. Next, the plasmids
would be transfected into mammalian cells and monitored for fluorescence using a fluorescent
microscope and FACS machine. Lastly, a Western Blot would be used to confirm the success of
the experiment and characterize the creation of GFP within the cell.
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The next set of the project was expected to take the last four months to finish. After proving the
success of the experiment, a new plasmid containing a genetic circuit for the regulation of the
Sortase A gene in response to light would be incorporated into the cell via the same set of
experiments. After incorporating the genetic circuit into mammalian cells along with the test
plasmids, the cells would be exposed to light and monitored for fluorescence in a time-specific
way.
Given the state of the pandemic before the project began, it was decided that the back up plan for
any time constraints would be to focus on the first half of the experiment and save the genetic
circuit for future iterations of the project. Due to lab closures from the Covid-19 pandemic, the
expected eight to nine month research period was shortened to two months. Because of extreme
loss of time, the back up plan was cut further, eliminating the opportunity for FACS and Western
Blot analysis.
1.10 Significance
If this new method is proven successful, it can have many potential applications in research and
drug development. In basic research, this procedure can improve upon current industry standards
to create a method that is faster, simpler, and higher yielding. It can also be used to develop novel
proteins and allow scientists to better understand basic protein function in vivo. Similarly, this
method can help scientists develop non-natural protein tags containing unnatural amino acids or
prosthetic groups, which cannot be encoded for in typical plasmid vectors. Lastly, if proven
successful, this method can be used to ligate any biomolecule-not just proteins. DNA, lipids, and
sugars are all candidate molecules that can be edited down the road for research and further
development of biomolecules.
In the realm of drug design, this new method can be used to aid in selectivity. If Sortase A
expression is regulated by a genetic circuit, ligation (activation) can be controlled using a
stimulus like light or radiation. This method can also be used to synthesize antibody drug
conjugates (ADCs) in vivo. In this case, Sortase A can bind a drug and antibody together,
creating a molecule that is better suited to locate the proper target and eliminate off-target effects.
Overall, the application of Sortase A as a protein ligase can help improve many areas of drug
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development, including cancer and immuno- therapy, by creating more selective and effective
drugs.
1.11 Team and Management
Our team equally shared the responsibilities of executing and optimizing experimental
procedures, maintaining bacterial and mammalian cell lines, collecting and analyzing data, and
communicating our conclusions with our advisor and peers. Dr. Zhang provided input and
guidance during weekly meetings, and graduate students Melina Huang and Lisa Jin, as well as
bioengineering student Ben Tan provided additional lab support in the execution of our bacterial
cell procedures.
1.12 Budget
Our team was granted a total of $1500 to use towards research supplies. Our needed supplies
exceeded the budget by approximately $100, but we were able to work around budget constraints
by sharing disposables, such as petri dishes, well plates, and collection tubes, with another group
from the same lab.
Table 1: Project Materials and Budget
Materials

Quantity

Price

Agarose Powder

25 g

In Storage

TAE Buffer

1L

In Storage

Sample Loading Buffer

3 x 0.5 mL

In Storage

DNA Ladder (1 kb)

0.5 mL

In Storage

LB Broth Media Powder

500 g

In Storage

11 x 50 µL/tube

$210.00

One Shot™ TOP10
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Competent Cells (108)
Luria Agar

100 g

In Storage

Ampicillin

5g

$26.00

Kanamycin

5g

$26.00

Tetracycline

25 g

$26.00

Petri Dishes

20

$11.99

Medium

500 mL

$52.50

HeLa Cells

1

$495.00

GlutaMAX Supplement

2 x 500 mL

$65.06

FBS, Heat Inactivated

50 mL

$84.75

PBS, pH 7.4

500 mL

$32.40

Red

100 mL

$14.14

DMSO

100 mL

$52.25

Conical Vials (10 or 15 mL)

50 Tubes

$17.99

Eppendorf Tubes (2 mL)

500 Tubes

$17.45

6-Well Plate

10 Plates

$13.00

Opti-mem Reduced Serum

dMEM, High Glucose,

Trypsin-EDTA (0.25%) Phenol
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ColumnPure MiniPrep Kit

1

In Storage

Fugene6 Transfection Reagent

1 mL

$435.00

Total Cost:

$1579.53

1.13 Timeline
The timeline of our experiment was greatly reduced due to the initial lab closure, as well as
additional, unexpected lab closures throughout the year. This resulted in a total experiment time
of two months in the wet lab. Our original plan was described in Section 1.8, however we had to
use our backup plan in order to adjust to the accelerated time frame. Refer to Appendix A for
our updated timeline.
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Chapter 2: Bacterial Transformation
2.1 Design Description
Bacterial cell culture is widely used in biomedical research, ranging from vaccines to antibody
generation [21,22]. Bacterial cells are often used for the production of simple, non glycosylated
proteins and proteins that don’t require post-translational modifications. This project relies on a
mammalian system because the proteins require post-translational modifications, however, a
bacterial expression system is used purely for plasmid amplification. Mammalian cell
transfection requires a particular ratio of plasmid DNA to cell density, but bacterial cells only
require one plasmid in order to uptake and amplify the plasmid DNA. This makes bacteria the
optimal expression system to amplify plasmids prior to mammalian transfection and expression.
2.2 Key Constraints
The key constraints included optimizing our procedures and following the same protocol for
each plasmid design. Antibiotic concentrations are also critical in ensuring only our transformed
bacteria are able to survive the cell culture. Low yields or improper purification of the plasmids
would push back mammalian transfection by a few days, which is critical as months of research
time were lost from COVID-19.
2.3 Expected Results
With proper bacterial transformation, the expectation is to see healthy and isolated colonies on
the agar plates, cell culture flasks with an OD600 reading greater than 0.6 after a day of growing,
and two bands per plasmid after gel electrophoresis analysis. More than two bands in gel
electrophoresis analysis indicates contamination.
2.4 Back-Up Plan
For plasmid purification, LAMDA Mini-Prep kits will be ordered to meet budget requirements.
In case this brand of Mini-Prep kits are unsatisfactory, stored Qiagen Mini-Prep kits from 2017
are available to use.
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2.5 Materials and Methods
2.5.1 Plasmid Design
The three recombinant plasmids (410, 411, 412) were designed by a previous team using ApE
software as seen in Appendix B-D [9]. Their full plasmids can be found in Appendix E-G.
Plasmids 88 and eGFP were previously created and stored by the Bioengineering Department as
seen in Appendix H and I. The recombinant plasmids were designed for optimal expression in
mammalian cells. Plasmids were amplified using Shot TOP 10 competent cells and purified
using a Qiagen Miniprep kit. Chinese hamster ovary (CHO) cells were passaged to a confluency
of 80% and transfected using Fugene6 transfection reagent. Our transfection consisted of 8 wells:
5 wells containing each plasmid separately to use as a control, and 3 wells containing a
combination of Sortase A with either 410, 411, or 412. After transfection, CHO cells were
observed every 24 hours for fluorescence.

Figure 3. Simplified design of Plasmids. Plasmid 88 contains the gene that encodes for Sortase A [9].

Figure 3 shows a simplified version of the plasmids. Labeled 1 - 5 are the peptide fragments that
will be included in the plasmids. The first three peptide fragments show the N-terminus of GFP.
All have a FLAG tag that will aid in Western Blot characterization at the end of the experiment,
as well as the LPETG motif that signals Sortase A. Fragment 2 has a TOP 1 peptide, which is an
epitope designed to have high affinity binding to the Sortase A intermediate’s SH3 domain.
Fragment 3 has a BOT 1 peptide, which is an epitope designed to have poor binding affinity to
the SH3 domain. These epitopes were found by the previous team using BioAI on an epitope
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database. Plasmid 410 is used as a negative control, or basal control, for efficiency. Because it
has unaltered binding, it should fluoresce at a dim level. Plasmid 411 is the test plasmid. It is
expected to show medium to high fluorescence because of its high affinity binding. Plasmid 412
is another negative control and should not fluoresce due to poor binding affinity. Lastly, the
plasmid 88 is the gene that encodes for Sortase A. This will allow the cell to produce the enzyme
and facilitate the reaction.
2.5.2 Amplification of Recombinant Plasmids
BL21 Competent E. coli cells were chosen for their efficiency and resiliency. The plasmids to be
amplified were sourced from last year’s iteration of this project, as the previous group was able
to generate and store the plasmid stock before COVID lab shutdowns.
Luria Agar plates were premade by the biology department and over-plated with antibiotics for
cell selection. Any cells that do not successfully uptake the plasmids should die, while the cells
that contain plasmids should live, as the plasmids contain antibiotic resistance genes. Plasmids
410, 411. 412, and Sortase A contain ampicillin resistance. The eGFP plasmids contain
kanamycin resistance. To overplate, a 4 mg/mL stock solution of ampicillin and kanamycin were
made by adding 0.8 grams of antibiotic powder to 200 mL LB broth. 250 uL of the correct
antibiotic were added to each corresponding agar plate. The antibiotic broth was spread around
the surface of the plates using sterile technique. The plates were incubated at room temperature
for at least 30 minutes with the lid on until the liquid was fully absorbed.
For bacterial transformation, five BL21 competent cell vials were organized, one for each
plasmid. 1 uL of plasmid 88 was added to a single vial. 1 uL of eGFP plasmid was added to
another vial, 1 uL of plasmids 410, 411, and 412 were added to their respective vials, then
incubated on ice for 30 minutes. The vials were heatshocked for exactly 40 seconds at 42°C
without shaking, then placed back on ice for an additional 2 minutes. Following the incubation
period, 250 uL of room temp LB Broth media was added to each vial, then capped tightly and
placed in the incubator for 1 hour at 37°C at 225 rpm. The contents of each vial were then plated
on respective Agar plates and incubated at 37°C for 12-16 hours.
The scale up procedure involved the 5 e.coli plates from transformation, micropipette and tips,
plastic vials, 500 mL Erlenmeyer flasks, and LB Broth media, and was conducted entirely under
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a bunsen burner using sterile technique. 1 mL of LB Broth was added to five vials, one
corresponding to each E. coli plate/plasmid. A micropipette tip was used to remove a single
colony from each E. coli plate and place it in the corresponding vial. The vials were then placed
in the shaker incubator at 37°C and 225 rpm for 4 hours. After 4 hours, each of the 5 Erlenmeyer
flasks were filled with 200 mL of LB Broth media with their respective antibiotic selection
markers at a concentration of 50 ug/mL. The contents of each vial were then transferred to their
corresponding Erlenmeyer flask, then placed in the shaker incubator at 37°C and 225 rpm for 4
hours. After this incubation period, the OD600 of each sample was taken by placing 1 mL of
culture in a spectrophotometer. A sample of plain LB Broth media was used to set a blank for the
machine. Each flask was expected to reach an OD600 reading >0.6. The OD600 reading for each
flask is listed in Table 2.
Table 2. OD600 Readings after Final Incubation
Plasmid Number

OD600 Reading

88

1.928

410

1.304

411

0.620

412

0.736

eGFP

0.627

2.5.3 Purification of Recombinant Plasmids
To purify the plasmids, a Qiagen Miniprep kit was used. First, the Erlenmeyer flasks containing
the final concentration of transformed E. coli were removed from the 4 °C refrigerator and
swirled in the shaker incubator for two minutes. Once the cells were resuspended, each culture
was harvested by transferring 1 mL into a 1.5 mL microcentrifuge tube. The cells were then
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centrifuged at 8000 rpm for 3 minutes. The supernatant was removed and each bacterial pellet
was resuspended in 250 µL of Buffer P1. 250 µL of Buffer P2 was added and each tube was
inverted gently 8 times. 350 µL of Buffer N3 was added and each tube was inverted gently 8
times. Each resuspension was centrifuged at 12000 rpm for 10 minutes. 800 µL of the
supernatant was removed and transferred to a spin column, and centrifuged at 13000 rpm for 1
minute. 750 µL of buffer PE was added to the spin column and centrifuged at 13000 rpm for 1
minute. Once again, 750 µL of buffer PE was added to the spin column and centrifuged at 13000
rpm for 1 minute. The flow-through was discarded and the spin column was centrifuged at 13000
rpm for 1 minute. Each spin column was transferred to a sterile 1.5 mL microcentrifuge tube. 50
µL of Buffer EB was added to the spin column and sat for 1 minute before being centrifuged at
13000 rpm for 1 minute. Each centrifuge step was run at 15 °C.
A larger scale miniprep procedure was used for flasks with a lower OD600 reading (below 1).
The Erlenmeyer flasks containing the final concentration of transformed E. coli were removed
from the 4 °C refrigerator and swirled in the shaker incubator for two minutes. Once the cells
were resuspended, each culture was harvested by transferring 5 mL into a 10mL centrifuge tube.
The cells were then centrifuged at 6000 rpm for 10 minutes. The supernatant was removed and
each bacterial pellet was resuspended in 250 µL of Buffer P1. Each resuspension was transferred
to its own sterile 1.5 mL microcentrifuge tube. 250 µL of Buffer P2 was added and each tube
was inverted gently 8 times. 350 µL of Buffer N3 was added and each tube was inverted gently 8
times. Each resuspension was centrifuged at 12000 rpm for 10 minutes. 800 µL of the
supernatant was removed and transferred to a spin column, and centrifuged at 13000 rpm for 1
minute. 750 µL of buffer PE was added to the spin column and centrifuged at 13000 rpm for 1
minute. Once again, 750 µL of buffer PE was added to the spin column and centrifuged at 13000
rpm for 1 minute. The flow-through was discarded and the spin column was centrifuged at 13000
rpm for 1 minute. Each spin column was transferred to a sterile 1.5 mL microcentrifuge tube. 50
µL of Buffer EB was added to the spin column and sat for 1 minute before being centrifuged at
13000 rpm for 1 minute. Each centrifuge step was run at 15 °C.
To check the DNA concentration of the final product from the minipreps, 1.2 µL of the final
solution was added to a nanodrop device. A blank was used containing 1.2 µL of the Buffer EB.
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The final concentrations of plasmid 88, plasmid 410, plasmid 411, plasmid 412, and plasmid
eGFP from the Miniprep are listed in Table 3, and from the Large Scale miniprep in Table 4.
Table 3. DNA Concentrations of Plasmids after Miniprep
Plasmid Number

Trial 1 (ng/µL)

Trial 2 (ng/µL)

Trial 3 (ng/µL)

88

342.7

377.6

334.5

410

212.0

199.9

231.4

411

60.0

28.5

29.0

412

38.2

37.2

49.0

eGFP

16.2

23.0

17.9

Table 4. DNA Concentrations of Plasmids after Large Scale Miniprep
Plasmid Number

Trial 4 (ng/µL)

Trial 5 (ng/µL)

411

98.0

80.8

412

129.5

144.9

eGFP

64.1

52.3
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2.6 Results and Discussion

Figure 4. Healthy Bacterial Plate. The plate was made using luria agar broth and 50 µg/mL ampicillin
concentration. The plate has isolated colonies, indicating that the e. Coli cells have been properly transformed with
the plasmid DNA and were plated properly. The other four plates displayed similar results to this plate with Plasmid
411.

After plating each of the different plasmids and incubating them overnight, each plate was
covered in bacterial colonies as seen in Figure 4. Each plate was healthy, as colonies were
circular, light yellow, and for the most part isolated. Every plate was covered in over a hundred
colonies, except for plasmid 88 which only contained three colonies on the plate. The differences
in these numbers can arise from a number of factors, such as differences in the vector design of
Sortase A and the GFP recombinant plasmids (410 - 412).
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Figure 5. Gel Electrophoresis after Plasmid Purification using LAMDA Mini-Prep Kits. The lamda
mini-prep kits confirmed that each of the bacterial cultures were properly transformed and contained the desired
plasmid DNA. This purification also contained genomic DNA, shown by the bands in the red box.

Initial plasmid purification was done using the LAMDA Mini-Prep Kits in an effort to meet the
budget requirements and acquire newer reagents. The Qiagen kits in storage were obtained back
in 2017, and purchasing a new kit was significantly more expensive than other alternatives. The
first trial with the LAMDA kits revealed genomic DNA, as seen in Figure 5. The second trial of
Mini-Prep was run using an optimized LAMDA protocol run at the same time as the Qiagen kit
in storage. The Qiagen kit ended up showing more promising results after gel electrophoresis
analysis, and was used in further plasmid purification steps.
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Figure 6. Gel Electrophoresis after Plasmid Purification using Qiagen Mini-Prep Kits. The Qiagen kits showed the
two bands as expected from the plasmid designs, and did not show any genomic DNA after optimization.

To optimize the Qiagen protocols for plasmid purification, a second wash step was implemented.
This allowed for the removal of genomic DNA from the final eluted product, as seen in Figure 6.
These finalized protocols were implemented for three to five trials depending on the DNA yield
obtained. Once enough plasmid DNA was obtained, the DNA was stored in a 4 °C refrigerator
until mammalian cells were ready for transfection.
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Chapter 3: Mammalian Cell Culture
3.1 Design Description
As previously noted, the majority of this project relies on a mammalian expression system due to
its ability to perform post translational modifications. This is key to evaluating the efficacy of
Sortase A’s binding ability, as the plasmid to be reconstructed codes for a GFP protein requiring
post translational modifications. Given that the plasmids were already amplified to achieve the
required amounts using bacterial expression systems, the use of mammalian expression systems
is simply a vessel through which Sortase A’s function can be evaluated to the best accuracy and
certainty.
3.2 Key Constraints
A major constraint involved optimizing the transfection protocol, especially finding the best
transfection reagent and dilution for the given cell line. The original transfection reagent used
was toxic to the original cell line, so both the cell line and transfection reagent were replaced.
CHO cells were used instead of HeLa variants and Fugene6 transfection reagent was used
instead of Lipofectamine 2000. The required ratio of transfection reagent to plasmid DNA also
varies depending on the cell line and project, so additional optimization experiments are required
to increase efficiency and form an official protocol. Lastly, due to COVID-related campus
shutdowns, we had to coordinate with other senior design groups to maintain the CHO cell lines
in preparation for future transfection trials.
3.3 Expected Results
Alongside the continued survival and proliferation of the CHO cells, the fluorescence of
transfection wells 88+410, 88+411, and eGFP were expected to confirm the success of the
mechanism. The combination of Sortase A with the test plasmids will confirm that Sortase A is
able to ligate peptide fragments in vivo to create a fully functional GFP. eGFP fluorescence is
used as a positive control and will confirm the success of the transfection protocol. If eGFP is
unable to fluoresce, this means the transfection procedure failed. Transfection wells 88, 410, 411,
412, and 88+412 are not expected to show fluorescence. These wells are used as negative
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controls to check for contamination, self-fluorescence, and Sortase A selectivity. If these wells
show fluorescence, it demonstrates either a flaw in the experimental design or execution of the
transfection.
3.4 Back-Up Plan
Although HeLa cells are typically resilient, lipofectamine is a toxic transfection reagent that can
kill mammalian cells. In case HeLa cells do not survive the transfection process, two additional
measures will be taken: CHO cells will be kept in storage as an alternative mammalian cell
option and Fugene6 will be ordered as an alternative transfection reagent.
3.5 Materials and Methods
3.5.1 CHO Cell Culture
CCL2 HeLa cells were originally chosen for our mammalian expression system because of their
resilience and immortality. However, the incorrect cell line was received from the manufacturer
and due to time constraints, CHO cells were used. CHO cells are a commonly used cell line as
they are robust and are known to produce large quantities of recombinant proteins. The CHO
cells were grown in 10 cm tissue culture plates and passaged every 48-96 hours, depending on
when they reached 80% confluency. Media was checked every 24 hours and changed when it
turned from a bright red to a reddish-orange color. For the first 5 passages after thawing, media
consisting of 15% Fetal Bovine Serum (FBS) in Dulbecco’s Modified Eagle Medium (dMEM)
was added to supplement the weakened cells. The following passages used media containing
10% FBS in dMEM.
To maintain cells for long-term use, a simple passaging procedure was performed. First, 10%
FBS media, Trypsin, and Phosphate-Buffered Saline (PBS) reagents were placed in a water bath
at 37 °C until reaching room temperature. Old media was aspirated from the plate and the cells
were washed with 1.5 mL of PBS, added to the side of the plate. The PBS was then aspirated off
and 2.0 mL of new PBS was added to the side of the plate as a second wash. The PBS was
aspirated off the plate and 1.5 mL of Trypsin was added dropwise, directly to the plate. The cells
were placed in the incubator for 2 minutes. Then, the bottom of the plate was gently tapped to
detach any remaining cells. 3mL of the 10% FBS media was added to the side of the plate to
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dilute the Trypsin and prevent the cells from lysing. The liquid from the plate was collected into
a 15 mL centrifuge tube and placed in the centrifuge for 3 minutes at 3000 rpm. Two new petri
dishes were filled with 8 mL of fresh media. For a 48 hour passage, the cell pellet was
resuspended in 4 mL of 10% FBS media. 2 mL of the final solution was added dropwise in a
circular motion to each plate. The plate was then gently tilted back and forth to stimulate cell
movement around the plate and prevent clumping in the center. The old plate was bleached and
the two new plates were stored in the incubator.
24 hours before a transfection procedure, cells were passaged in a special way and replated in 6
well plates. Cell confluency was checked to estimate cell count on the plate, ensuring at least 6 x
104 cells in each well for a total of 8 wells. It was assumed that an 80% confluent 10 cm plate
contained 8 x 105 cells. Two 6 well plates were used and each well was filled with 2 mL of
Opti-mem medium. Opti-mem medium was used for transfection because it does not contain
serum. Cells were passaged using the protocol listed above, up until resuspension of the pellet.
Cells were resuspended in 2.6 mL of Opti-mem medium. Each well received 200 µL of
resuspended cells, distributed dropwise in a circular motion. Once the cells were added, the plate
was gently rocked back and forth to spread the cells and placed in the incubator for 12-16 hours.
Any remaining resuspended cells were bleached.
3.5.2 Plasmid Transfection
Transfection was performed 12-16 hours after plating the cells. The well lay-out was as follows:
well 1 contained plasmid 88, well 2 contained plasmid 410, well 3 contained plasmid 411, well 4
contained plasmid 412, well 5 contained plasmids 88+410, well 6 contained plasmids 88+411,
well 7 contained plasmids 88+412, and well 8 contained the plasmid for eGFP. The Fugene6
transfection reagent was used as it is less toxic and more effective than the traditional
Lipofectamine 2000 reagent. The transfection followed a 1:3 ratio of plasmid DNA to
transfection reagent. 6 µL of Fugene6 was used along with 2 µL of plasmid DNA. The total
plasmid mass was calculated from the nanodrop concentration results after the Miniprep
procedure. The amounts of plasmid DNA listed in Table 4 include the tube number of the
associated round.
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Opti-mem media was warmed to room temperature using a 37 °C water bath. Fugene6 was left in
the biohood and warmed to room temperature. After the media was warmed up, the Fugene6
reagent was gently inverted. Next, 94 ul of Opti-mem medium was pipetted into eight 1.5 mL
microcentrifuge tubes. Next, 6 µL of Fugene6 reagent was added to each tube directly into the
Opti-mem medium, making sure to not let the undiluted reagent make contact with the sides of
the tube. Each tube was gently pipetted up and down and sat for 5 minutes at room temperature.
Next, plasmid DNA was added based on Table 5 and mixed by pipetting up and down. The
plasmid DNA-transfection reagent mixture was left to incubate at room temperature for 15
minutes. 60 µL of our plasmid DNA-transfection reagent mixture was added to each
corresponding well in our 6 well plate and mixed by tilting the plate back and forth. The plates
were incubated for 24 hours. After 24 hours, the old media was aspirated to remove any cell
debris and replaced with Opti-mem medium and 10% CaCl2 solution. A CaCl2 wash was chosen
because Sortase A relies on Ca2+ as a cofactor.
Table 5. Fugene6 Transfection Trial 1 of Designed Recombinant Plasmids
Plates

Plate 1

Plate 2

Plate 3

Plate 4

Plate 5

Plate 6

Plate 7

Plate 8

Plasmids #

88

410

411

412

88 &

88 &

88 &

eGFP

410

411

412

Plasmid

2

2

2

2

1+1

1+1

1+1

2

Plasmid

5.30

10.0

20.90

19.53

88R2:

88R2:

88R2:

27.82

Amount (ul)

R2

R2

R3

R3

2.64 +

2.64 +

2.64 +

R3

410R2:

411R3:

412R3:

5.0

10.45

9.77

6

6

6

Amount (ug)

Fugene6 (μl)

6

6

6

6

6
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3.5.3 Fluorescent Analysis
After transfection, the CHO cells were monitored for GFP expression using a Keyence
Fluorescence Microscope. Cells were observed for a fluorescent signal every 24 hours after
transfection for a total of 3 days. First, a magnification of 2x was used to locate major areas of
fluorescence on the plate. Next, a magnification of 20x was used to take fluorescent and
brightfield images of each well. These images were overlaid to visualize which cells were
fluorescing. Mutated or floating cells with a fluorescent signal were not imaged or counted as
true fluorescence for this experiment
3.6 Results and Discussion

Figure 7. Mammalian CHO Cell Culture at 80% Confluency

The project was originally designed for HeLa cells because of their resilience and immortality.
However, HeLa variants were received and were unable to survive our transfection and had
difficulty reaching 80% confluency. Figure 7 shows our backup cells, CHO cells. CHO cells are
large, robust cells with a rod-like structure. Cells were grown to 80% confluency, which means
taking up 80% of the tissue plate before they are passaged and allocated into new plates. Cells
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are passaged at this confluency to ensure even distribution of media nutrients among cells and
prevent overcrowding.

Figure 8. Transfection using Lipofectamine. Transfection resulted in cell death and mutation after using
lipofectamine. No results were able to be obtained using a fluorescent microscope.

The first transfection involved HeLa variant cells and Lipofectamine 2000 transfection reagent.
Though HeLa cells are typically resilient, the variant cells were unable to survive the harsh
reagent after 24 hours. Figure 8 shows an image of the cells 24 hours after transfection. The cells
lost their typical fibroblast shape, which indicates they are dead or mutated. This transfection
trial inspired a rewrite of the protocol, using CHO cells and nontoxic Fugene6 transfection
reagent instead of HeLa variants and Lipofectamine.
The transfection trials in Figures 9 - 15 show CHO cells that used the Fugene6 transfection
reagent. Images were not taken in the same location each day and only represent a small fraction
of the culture plate. Brightfield images were overlaid with their fluorescent counterparts for each
figure.
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Figure 9. Fluorescent Images of eGFP at (A) 24 hours, (B) 48 hours, and (C) 72 hours.

Figure 9 shows fluorescence, indicating a successful transformation. This plasmid acted as the
positive control to confirm the protocol was valid. It is important to note that the transfection
efficiency is low in these images. This is most likely due to the fact that this mechanism relies on
the combination of two plasmids to fluoresce. If the plasmid concentration is too low, cells will
only uptake one plasmid or the other, resulting in no fluorescence. Overall, this result is
promising, but the efficiency indicates the need for further optimization trials.

Figure 10. Fluorescent Images of Plasmid 88 at (A) 24 hours, (B) 48 hours, and (C) 72 hours.

Figure 10 shows the results of our first negative control, the plasmid encoding for Sortase A. No
fluorescence is expected from this plasmid, since the mechanism relies on the combination of
both Sortase A and the test plasmid. This is a promising result, as there is no contamination of
other plasmids and demonstrates that Sortase A is incapable of self-fluorescence.

34

Figure 11. Fluorescent Images of Plasmid 410 at (A) 24 hours, (B) 48 hours, and (C) 72 hours.

Figure 12. Fluorescent Images of Plasmid 411 at (A) 24 hours, (B) 48 hours, and (C) 72 hours.

Figure 13. Fluorescent Images of Plasmid 412 at (A) 24 hours, (B) 48 hours, and (C) 72 hours.

Figures 11 -13 show the test plasmids by themselves, without the presence of Sortase A. These
are all negative controls, as the mechanism relies on the combination of Sortase A with a test
plasmid. This is a promising result, as there is no fluorescence. It shows that the plasmids are
incapable of self-fluorescence and that the cell is incapable of ligating the GFP fragments on its
own.
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Figure 14. Fluorescent Images of Plasmids 88+410 at (A) 24 hours, (B) 48 hours, and (C) 72 hours. Fluorescent
images are shown in (D) - (F).

Figure 14 shows our basal control plasmid in combination with Sortase A. A dim fluorescence is
expected in this plasmid, as it was not enhanced for optimal Sortase A binding. A red circle
highlights a small fluorescent signal in the original fluorescent images that is too weak to be seen
with the overlay feature. Though at a low level, this signal could be significant, as the negative
controls didn’t show this level of dim fluorescence. This signal indicates a promising result,
however, nothing can be concluded from this data until transfection efficiency is increased.
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Figure 15. Fluorescent Images of Plasmids 88+411 at (A) 24 hours, (B) 48 hours, and (C) 72 hours. Fluorescent
images are shown in (D) - (F).

Figure 15 shows the high affinity plasmid in combination with Sortase A. This trial is expected
to show medium to high fluorescence, as the plasmid was designed for optimal Sortase A
binding. A red circle highlights a fluorescent signal that is strong enough to be seen in both the
fluorescent and overlay images. Though this signal is also at a low level, it could be significant,
as the basal control didn’t show this level of fluorescence in the overlay image. This signal
indicates a promising result, however, nothing can be concluded from this data until transfection
efficiency is increased.

Figure 16. Fluorescent Images of Plasmids 88+412 at (A) 24 hours, (B) 48 hours, and (C) 72 hours.

Figure 16 shows the lowest affinity plasmid in combination with Sortase A. This plasmid was
designed to have poor binding affinity with Sortase A and should not show fluorescence. This is
a promising result, as no fluorescent signal was obtained from this trial, indicating that Sortase A
can be reasonably selective and must be signaled by an optimal motif in order to ligate peptide
fragments.
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Chapter 4: Discussion and Conclusion
Our study demonstrates that Sortase A is a promising candidate for in vivo protein ligation. The
transfection wells that contained negative control plasmids showed no sign of fluorescence,
meaning there were no issues with the experimental design or execution. The transfection well
that contained eGFP as a positive control showed fluorescence, meaning the transfection
protocol was successful. However, transfection efficiency was lower than expected, indicating
that further optimization studies need to be performed to increase efficiency and effectiveness of
the procedure. Lastly, the test plasmids showed low signs of fluorescence. The fluorescent
signals were dim but significant, as no negative controls showed signs of fluorescence. Similarly,
transfection efficiency was low in these wells and transfection optimization is required to
improve the results of the experiment. Overall, the results were extremely promising, but a larger
transfection efficiency is needed to come to a formal conclusion about Sortase A’s ability to
ligate peptides in vivo.
4.1 Future Works
4.1.1 Transfection Optimization
Due to the time constraints from the global pandemic, Fugene6’s generic protocol for
transfection was used. However, Promega recommends optimizing the transfection protocol for
the specific cells as each cell line responds differently to the transfection reagent. These
optimization protocols are listed in Table 6, along with additional optimization trials specific to
our experimental design. The use of two plasmids means that the transfection reagent must
transfect both plasmids into the cell. The final volume, DNA amount, and reagent volume were
doubled to account for the extra plasmid. If only one plasmid is able to enter the cell, there will
be no GFP expression and further optimization is needed.
Table 6. Transfection Optimization Trials
Parameters

Promega Optimization

Additional Optimization
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Ratio of

6:1

4:1

3:1

1.5:1

6:1

4:1

3:1

1.5:1

100 µl

100 µl

100 µl

100 µl

200 µl

200 µl

200 µl

200 µl

DNA

2 µg

2 µg

2 µg

2 µg

4 µg

4 µg

4 µg

4 µg

Reagent

12 µl

8 µl

6 µl

3 µl

24 µl

16 µl

12 µl

6 µl

reagent to
plasmid

Final volume

4.1.2 Flow Cytometry
Once the transfection protocols have been optimized, the visualization of cells will need to be
analyzed by flow cytometry. Fluorescence should be visible in most cells, and will not be able to
be visualized. Flow cytometry will be able to quantitatively analyze the efficiency of the
transfection reagent as well as the different combinations of plasmid designs. With the TOP1 and
SH3 domains having the highest affinity for each other, plasmids 88+411 are expected to have
the highest efficiency. Plasmids 88+412 contain the BOT1 and SH3 domains which have no
affinity for each other and are expected to have the lowest efficiency. Plasmids 88+410 do not
contain additional domains and are expected to have a middle efficiency.
4.1.3 Western Blot
Western blot analysis is needed to characterize the fluorescent protein from the transfection
trials. FLAG antibodies will be used to bind to the FLAG tag included in the original peptide
sequence and confirm that Sortase A was able to create a fully functional GFP. This
characterization will also prove that fluorescence was indeed due to Sortase A and not
contamination or other potential outside factors. Locating a band at 27 kDa will confirm the
presence of GFP.

39

4.1.4 Genetic Circuit
Implementation of a genetic circuit is needed to regulate the expression of Sortase A and prove
its ability to ligate selectively. In future iterations of the project, a genetic circuit that responds to
light will be used to activate Sortase A expression. It will be integrated into the protein using an
additional plasmid vector. This experiment will follow a similar protocol, beginning with
bacterial transformation and ending with fluorescent microscopy analysis. In fluorescent
analysis, cells will be kept in the dark and monitored for fluorescence for 48 hours. Then, cells
will be exposed to light to trigger the expression of Sortase A. After exposure, cells will be
monitored every eight hours for 72 hours to determine the time-selectivity of Sortase A.
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Chapter 5: Engineering Standards and Realistic Constraints
5.1 Science, Technology, and Society
If proven successful, Sortase A ligation can be used in future applications as an aid in selective
drug development. When Sortase A’s gene is regulated by a genetic circuit, scientists have the
ability to turn its protein expression on and off. This can be used to site-selectively and
time-sensitively control the formation of protein drugs within the cell. One particular application
that could have a large impact on society is cancer drug development. Many current cancer
treatments, like chemotherapy, are not selective drugs and kill healthy cells, causing unwanted
side effects. In addition, cancer treatments like immunotherapy have no on/off switch, which
sometimes causes unwanted inflammation and puts the body into unnecessary immune system
overdrive. The use of Sortase A to respond to a stimulus and act site and time selectively can
greatly improve the quality of life and treatment outcome of many patients worldwide. In
addition, Sortase A’s applications can reach far beyond protein ligation; if signaled by the
LPXTG motif, Sortase A should be able to ligate other drug molecules such as lipids, DNA,
sugars, and more. The use of Sortase A as a ligating molecule can greatly improve the current
field of medicine and create more effective drugs.
5.2 Civic Engagement
In order to become a commercial drug in the United States, Sortase A will need to be approved
by the Food and Drug Administration (FDA). The FDA has a five part process to achieve
approval: discovery/concept, preclinical research, clinical research, and FDA review and
post-market safety monitoring [23]. Sortase A is currently in the beginning stages of discovery
and concept development. To complete this stage, further transfection optimization trials must be
completed to increase transfection efficiency and confirm Sortase A’s ligation ability. Next, a
genetic circuit must be introduced to regulate the activity of Sortase A and prove that it can act
site and time selectively upon activation. Lastly, Sortase A and a genetic circuit can be paired
with a specific drug, allowing Sortase A to fully generate and regulate a protein drug within the
body. The second stage involves testing the Sortase A drug on animals to ensure the
effectiveness and safety of the drug. After reaching satisfactory levels in animal models, the drug
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will move to clinal models in humans. Three stages of human trials will be performed: phase 1,
phase 2, and phase 3. Phase 1 assesses the safety and side effects of the drug with a small pool of
healthy volunteers. Phase 2 monitors the efficacy of the drug through control and blind studies.
Phase 3 is large scale testing using randomized groups and is the final clinical stage of drug
development. The last step in FDA approval is post-market safety monitoring. After the drug is
approved for use in the United States, surveillance trials are ordered to observe efficacy, quality
of life, cost-effectiveness, and compare the drug with similar market products [24].
5.3 Ethical
Drug related side effects impact many patients worldwide, making the need for specific and
effective drugs extremely important. Sortase A’s potential ability to ligate molecules selectively
could improve patient quality of life and increase survival rates for many. This research aims to
improve upon current medicines for cancer and other debilitating diseases by creating an on/off
switch, which would reduce side effects and unwanted inflammation. Though this technology
has the potential to improve the lives of many, it is also important to analyze the potential ethical
issues with the research. One of the biggest ethical concerns of the project is the use of the
controversial HeLa cell line. HeLa cells were obtained non-consensually from Henrietta Lacks,
an African American woman with cervical cancer. Though many scientists worldwide use this
resilient cell line, it is important to acknowledge the origin of the lines. Because this project
doesn’t require the specific use of HeLa cells, the cell line was switched to less controversial
CHO cells.
5.4 Usability and Sustainability
This research aims to improve upon current industry standards, particularly EPL. Though EPL is
effective, it is a complicated procedure that leaves room for error. This research overcomes the
challenges associated with EPL by eliminating the need for excess cysteines, therefore limiting
side reactions. It also has a more streamlined protocol that allows cells to do most of the work,
eliminating more opportunities for human error. Once proven, this method should have a higher
product yield than EPL, as it should correctly fold all proteins ligated. Lastly, this method should
be a more cost-effective and sustainability approach to protein ligation; because this method uses
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an enzyme to ligate fragments, little enzymes and reagents are needed to catalyze the reaction.
This is an improvement from EPL’s 1:1 ratio requirement of protein to intein.
5.6 Health and Safety
Though Sortase A has the potential to act as a selective drug and improve the lives of patients, its
mechanism needs to be studied further before clinical or preclinical trials begin. Sortase A
responds to a LPXTG motif in order to ligate molecules, however, more research needs to be
done to determine what types of molecules naturally contain LPXTG. If Sortase A is used as a
drug, it needs to act selectively and only ligate the desired molecules. The LPXTG motif is found
naturally in bacterial cells, but more research needs to be done to ensure that this motif doesn’t
exist naturally in human proteins. If so, Sortase A would need to be further edited to prevent the
ligation of natural proteins within the body.
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Appendix
Appendix A:
Q2

Q1
Task

Oct

Nov

Dec

Jan

Q3

Feb March April

May

June

Complete lab access forms
Receive lab training
Create supplies list
Write protocols
Order supplies
Gain lab access

*note, lab closed for most of
March and April

Bacterial transformation
Bacterial cell culture
Plasmid Miniprep
Gel Electrophoresis
Mammalian cell culture
Plasmid transfection
Fluorescent Microscopy
if time

FACS
if time

Western Blot
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APPENDIX B: RECOMBINANT PLASMID 410 SEQUENCE
Recombinant plasmid 410 was designed on ApE (version 2.0.61) using the pEF-GFP vector
backbone from Addgene [9]. Plasmid 411 is 6353 nucleotides long.
GTCGACATTGATTATTGACTAGATCATCGCGTGAGGCTCCGGTGCCCGTCAGTGGGC
AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAA
CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGG
CTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG
AACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGT
TCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCA
CGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGG
GAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCC
TGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTC
GCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTT
TTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGG
TTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCG
AGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGG
CCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGC
AAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCC
CTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGA
GTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTC
CACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTAC
GTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTG
GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGC
CCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTT
TTTCTTCCATTTCAGGTGTCGTGAGGAATTCGCCACCATGAGTAAAGGAGAAGAACT
TTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAA
ATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAA
ATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTC
TCTTATGGTGTTCAATGCTTTTCAAGATACCCAGATCATATGAAACGGCATGACTTTT
TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAAGATG
ACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAAT
48

AGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAA
ATTGGAATACAACTATAACTCACACAATGTATACATCATGGCAGACAAACAAGACT
ACAAAGACGATGATGACAAACTGCCTGAAACCGGTTAATTAATAAAGGAAATTTAT
TTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCAGGTACCGCTCCGGTGCCC
GTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTC
GGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGT
CGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGT
AGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGC
CGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGA
ATTACTTCCACGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGG
AAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTG
AGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTC
GCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGC
TGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACAC
TGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCAC
ATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGT
CTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGC
CCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCG
CTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCG
GGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTT
CATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCT
TTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCC
ACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCT
TGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGT
TCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGCTAGCCACCATGGGAGGTGGAG
GTGGAGACTACAAAGACGATGATGACAAGAAGAATGGAATCAAAGTTAACTTCAAA
ATTAGACACAACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAA
TACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACA
ATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTT
TGTAACAGCTGCTGGGATTACACATGGCATGGATGAACTATACAAATAAAGCGGCC
GCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCC

49

TGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCA
TGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAA
TAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATC
ATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCCATATGC
TGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGAAACAGCCC
CCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTA
TATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTAC
TAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTCTCTTA
TGGAGATCCCTCGACCTGCAGCCCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCC
TGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAA
GTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTC
ACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCGGATCCGCATCTCAATTAG
TCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGT
TCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGG
CCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAG
GCTTTTGCAAAAAGCTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAA
TAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTG
TCCAAACTCATCAATGTATCTTATCATGTCTGGATCCGCTGCATTAATGAATCGGCC
AACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTG
ACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG
TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAA
GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAG
GCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA
ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCT
CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG
CGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGC
TCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCC
GGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCA
GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT
GAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCT
GCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAA
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CCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAA
AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACG
AAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA
TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTT
GGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTAT
TTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGG
CTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTC
CAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCT
GCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGT
AGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG
TCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGA
GTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC
GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCAT
AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAA
CCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAA
TACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA
CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATG
TAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTG
GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACG
GAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGG
GTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGG
APPENDIX C: RECOMBINANT PLASMID 411 SEQUENCE
Recombinant plasmid 2 was designed on ApE (version 2.0.61) using pEF-GFP vector backbone
from Addgene [9]. Plasmid 411 is 6548 nucleotides long, and includes the TOP1 and SH3
domains that increase GFP expression.
GTCGACATTGATTATTGACTAGATCATCGCGTGAGGCTCCGGTGCCCGTCAGTGGGC
AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAA
CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGG
CTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG
51

AACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGT
TCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCA
CGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGG
GAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCC
TGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTC
GCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTT
TTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGG
TTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCG
AGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGG
CCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGC
AAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCC
CTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGA
GTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTC
CACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTAC
GTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTG
GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGC
CCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTT
TTTCTTCCATTTCAGGTGTCGTGAGGAATTCGCCACCATGAGTAAAGGAGAAGAACT
TTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAA
ATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAA
ATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTC
TCTTATGGTGTTCAATGCTTTTCAAGATACCCAGATCATATGAAACGGCATGACTTTT
TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAAGATG
ACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAAT
AGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAA
ATTGGAATACAACTATAACTCACACAATGTATACATCATGGCAGACAAACAAGACT
ACAAAGACGATGATGACAAAGCTCCAGCCTTTCCACCTCCTAGCCCTCCACTGCCTG
AAACCGGTTAATTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTT
TGTGTCTCTCAGGTACCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCAC
AGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGT
GGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGG

52

GTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACG
GGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCT
TTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACGCCCCTGGCTGCAGTACG
TGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCG
CTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCC
GCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCT
AGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTT
GTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGC
GACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCG
GCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTG
GCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCA
CCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAA
ATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAA
AGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCG
TCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGG
GAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAG
GCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCT
TGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGT
CGTGAGCTAGCCACCATGGGAGGTGGAGGTGGAGACTACAAAGACGATGATGACAA
GAATGATCCTAACCTCTTTGTCGCACTGTATGATTTCGTCGCCTCTGGTGACAATACC
CTCAGCATTACTAAAGGAGAGAAGCTGAGGGTGCTGGGATACAATCACAACGGTGAG
TGGTGCGAGCCTCAGACAAAGAACGGACAGGGCTGGGTCCCTTCCAACTACAAGA
ATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTCAA
CTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCA
GACAACCATTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAG
AGACCACATGGTCCTTCTTGAGTTTGTAACAGCTGCTGGGATTACACATGGCATGGA
TGAACTATACAAATAAAGCGGCCGCACTCCTCAGGTGCAGGCTGCCTATCAGAAGG
TGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCCCT
CTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAAT
AAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGG
AAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGA

53

GTTTGGCAACATATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAG
GTCATCAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCT
TGACTTGAGGTTAGATTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCC
TAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCA
GTCATAGCTGTCCCTCTTCTCTTATGGAGATCCCTCGACCTGCAGCCCAAGCTTGGC
GTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACAC
AACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTA
ACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTG
CCAGCGGATCCGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTT
TTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGT
GAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTAACTTGTTTATTGCAGC
TTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTT
TTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGG
ATCCGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGG
CGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAG
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAAC
GCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGG
CCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATC
GACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACC
TGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTA
TCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGT
TCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGT
ATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA
GAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG
GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCA
AGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTA
CGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGA
TTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCA

54

ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG
GCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCG
TGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATAC
CGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGA
AGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAAT
TGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTT
GCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCT
CCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCG
GTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCA
CTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCT
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGAC
CGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTT
TAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTAC
CGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCAT
CTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAA
AAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAAT
ATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTAT
TTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGG
Appendix D: RECOMBINANT PLASMID 412 SEQUENCE
Recombinant plasmid 412 was designed on ApE (version 2.0.61) using the pEF-GFP vector
backbone from Addgene [9]. Plasmid 412 is 6548 nucleotides long, and includes the BOT1 and
SH3 domains that decrease GFP expression.
GTCGACATTGATTATTGACTAGATCATCGCGTGAGGCTCCGGTGCCCGTCAGTGGGC
AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAA
CCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGG
CTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTG
AACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGT
TCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCA
CGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGG
GAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCC
55

TGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTC
GCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTT
TTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGG
TTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGA
GGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGG
CCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGC
AAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCC
CTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGA
GTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTC
CACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTAC
GTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTG
GGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGC
CCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTT
TTTCTTCCATTTCAGGTGTCGTGAGGAATTCGCCACCATGAGTAAAGGAGAAGAACT
TTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAA
ATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAA
ATTTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTC
TCTTATGGTGTTCAATGCTTTTCAAGATACCCAGATCATATGAAACGGCATGACTTTT
TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTTCAAAGATG
ACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAAT
AGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAA
ATTGGAATACAACTATAACTCACACAATGTATACATCATGGCAGACAAACAAGACT
ACAAAGACGATGATGACAAAGCTGCTGCAATGCAGAAACCTAGCCTGCCACTGCCT
GAAACCGGTTAATTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTT
TTTGTGTCTCTCAGGTACCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCC
ACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAG
GTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGA
GGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAA
CGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCT
CTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACGCCCCTGGCTGCAGTA
CGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTG
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CGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGG
CCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTC
TCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGT
CTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGC
GGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGC
GCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGC
CTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGG
CACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCA
AAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGA
AAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGC
CGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGG
GGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTA
GGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGAT
CTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGT
GTCGTGAGCTAGCCACCATGGGAGGTGGAGGTGGAGACTACAAAGACGATGATGAC
AAGAATGATCCTAACCTCTTTGTCGCACTGTATGATTTCGTCGCCTCTGGTGACAATA
CCCTCAGCATTACTAAAGGAGAGAAGCTGAGGGTGCTGGGATACAATCACAACGGT
GAGTGGTGCGAGCCTCAGACAAAGAACGGACAGGGCTGGGTCCCTTCCAACTACAA
GAATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTC
AACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTAC
CAGACAACCATTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAG
AGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCTGCTGGGATTACACATGGCATG
GATGAACTATACAAATAAAGCGGCCGCACTCCTCAGGTGCAGGCTGCCTATCAGAA
GGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGATCTTTTTCC
CTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTA
ATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTC
GGAAGGACATATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTA
GAGTTTGGCAACATATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAG
AGGTCATCAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGC
CTTGACTTGAGGTTAGATTTTTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATC
CCTAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCC
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CAGTCATAGCTGTCCCTCTTCTCTTATGGAGATCCCTCGACCTGCAGCCCAAGCTTG
GCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCAC
ACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGC
TAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGT
GCCAGCGGATCCGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCC
CATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAG
TGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTAACTTGTTTATTGCAG
CTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTT
TTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTG
GATCCGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGG
GCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGA
GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAA
CGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG
GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAAT
CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTT
TCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATAC
CTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGT
ATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCG
TTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAG
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGG
TATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGA
AGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTT
GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGC
AAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCT
ACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAG
ATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATC
AATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGA
GGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTC
GTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATA
CCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGG
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AAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAA
TTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGT
TGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGC
TCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCG
GTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCA
CTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCT
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGAC
CGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTT
TAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTAC
CGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCAT
CTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAA
AAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAAT
ATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTAT
TTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGG
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Appendix E: Plasmid 410 Vector Design.
The pEF-GFP vector plasmid was used for its small size and expression in mammalian cells. The
GFP gene was spliced into two segments, with the N-terminus containing the LPETG motif, and
the Gly5 chain on the C-terminus. These were 471 and 245 nucleotides respectively. The
recombinant plasmid includes ampicillin for bacterial resistance, a kozak sequence for translation
efficiency, and a FLAG sequence for western blot analysis. Additional elements include an EF1
alpha promoter, origin of replication, start codon, stop codon, and the polyadenylation signal [9].
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Appendix F: Plasmid 411 Vector Design.
The plasmid design has the same features as plasmid 410, with the addition of the TOP1 and
SH3 domains, which have a high binding affinity for each other. This recombinant plasmid is
expected to have a higher expression of GFP [9].
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Appendix G: Plasmid 412 Vector Design.
The plasmid design has the same features as plasmid 410, with the addition of the BOT1 and
SH3 domains, which do not have a binding affinity for each other. This recombinant plasmid is
expected to have minimal expression of GFP [9].

Appendix H: RECOMBINANT PLASMID 88 SEQUENCE
Recombinant plasmid 88 encodes for Sortase A and is 710 base pairs long. The Sortase A gene is
621 base pairs with a protein sequence of 206 amino acids.
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NTGTCGTGAGGATTAGCTTGGTACTAATACGACTCACTATAGGGAGACCCAAGCTGG
CTAGGTAAGCTTGGTACCGAGCTCGGATCCACTAGTATGGGCCAAGCTAAACCTCAA
ATTCCGAAAGATAAATCAAAAGTGGCAGGCTATATTGAAATTCCAGATGCTGATATT
AAAGAACCAGTATATCCAGGACCAGCAACACCTGAACAATTAAATAGAGGTGTAAG
CTTTGCAGAAGAAAATGAATCACTAGATGATCAAAATATTTCAATTGCAGGACACA
CTTTCATTGACCGTCCGAACTATCAATTTACAAATCTTAAAGCAGCCAAAAAAGGTA
GTATGGTGTACTTTAAAGTTGGTAATGAAACACGTAAGTATAAAATGACAAGTATA
AGAGGTGTTAAGCCAACAGATGTAGAAGTTCTAGATGAACAAAAAGGTAAAGATAA
ACAATTAACATTAATTACTTGTGATGATTACAATGAAAAGACAGGCGTTTGGGAAA
AACGTAAAATCTTTGTAGCTACAGAAGTCAAAGAATTCTGCAGATATCCAGCACAGT
GGCGGCCGCTCGAGTCTAGAGGGCCCTTCGAACAAAAACTCATCTCAGAAGAGGAT
CTGAATATGCATACCGGTCATCATCACCATCACCATTGAGTTTAAACCCGCTGATCA
GCCTCGACTGTGCCTTCTAGTTGCCAGCCATC
APPENDIX I: eGFP PROTEIN SEQUENCE
The DNA sequence is 717 base pairs and the protein sequence is 239 amino acids long [25].
MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWP
TLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEG
DTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSV
QLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMD
ELYK
APPENDIX J: eGFP Plasmid Vector.
The pEGPF C2 plasmid used was created by BD Biosciences and contains kanamycin resistance
[26].
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